Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update
-
Rita Passerini
Abstract
Background: CA 19-9 is a marker principally related to pancreatic and gall bladder cancer. Although its determination has no value in screening for these malignancies, it is used in post-operative monitoring and during chemotherapeutic treatment of confirmed disease. Measurements during follow-up must be comparable and must be performed with standard, validated methods.
Methods: We compared four routinely used analytical systems for CA 19-9 determination: the Architect i2000 and AxSYM systems from Abbott Laboratories, the Elecsys 1010 from Roche Diagnostics, and the KRYPTOR system from Brahms Diagnostics. We evaluated the analytical performance of the four systems and compared measurements of CA 19-9 values, which covered the whole analytical range.
Results: The analytical performance and accuracy of the four systems were fairly good, but Passing-Bablok regression and mountain plots showed significant differences in CA 19-9 values measured with the four platforms.
Conclusions: Our data indicate that during tumor follow-up, the use of the same system is appropriate to avoid the risk of a variation due to the method rather than the disease. Moreover, whenever a change in analytical equipment is required, careful analysis of CA 19-9 results must be undertaken.
Clin Chem Lab Med 2007;45:100–4.
References
1. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol1990;85:350–5.Search in Google Scholar
2. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jorgensen J, Wolf H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem1999;45:54–61.Search in Google Scholar
3. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA 19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol1999;94:1941–6.10.1111/j.1572-0241.1999.01234.xSearch in Google Scholar
4. Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, et al. Serum CA 19-9 in the post surgical follow-up of patients with pancreatic cancer. Cancer1987;60:2428–31.10.1002/1097-0142(19871115)60:10<2428::AID-CNCR2820601013>3.0.CO;2-OSearch in Google Scholar
5. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol1988;6:462–8.10.1200/JCO.1988.6.3.462Search in Google Scholar
6. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer2003;89:1413–7.10.1038/sj.bjc.6601263Search in Google Scholar
7. Micke O, Bruns F, Kurowski R, Horst E, de Vries AF, Hausler JW, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys2003;57:90–7.10.1016/S0360-3016(03)00524-8Search in Google Scholar
8. Architect CA 19-9 List No. 6C04, Instruction manual. Abbott Laboratories, 1998.Search in Google Scholar
9. AxSYM CA 19-9 List No. 7A50, Instruction manual. Abbott Laboratories, 2003.Search in Google Scholar
10. Elecsys CA 19-9 Immunoassay List No 11776193, Instruction manual. Roche, 2004.Search in Google Scholar
11. KRYPTOR CA 19-9 List No 807.100, Instruction manual. Brahms, 2004.Search in Google Scholar
12. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science1977;198:679–84.10.1126/science.333584Search in Google Scholar
13. Passing H, Bablok W. A new biometrical procedure for testing the equality for measurement from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemestry, part I. J Clin Chem Clin Biochem1983;21:709–20.10.1515/cclm.1983.21.11.709Search in Google Scholar
14. Krouwer JS, Monti KL. A simple, graphical method to evaluate laboratory assays. Eur J Clin Chem Clin Biochem1995;33:525–7.Search in Google Scholar
15. Wu JT, Chang J. Chromatographic characterization of CA 19-9 molecules from cystic fibrosis and pancreatic carcinoma. J Clin Lab Anal1992;6:209–15.10.1002/jcla.1860060408Search in Google Scholar
16. Stern P, Friedecky B, Bartos V, Bezdckova D, Vavrova J, Uhrova J, et al. Comparison of different immunoassay for CA 19-9. Clin Chem Lab Med2001;39:1278–82.10.1515/CCLM.2001.205Search in Google Scholar
©2007 by Walter de Gruyter Berlin New York
Articles in the same Issue
- CCLM: Bringing advances in laboratory medicine to the “New World”
- Diagnostic approach to inherited bleeding disorders
- Linking laboratory and medication data: new opportunities for pharmacoepidemiological research
- Association between polymorphisms of ACE, B2AR, ANP and ENOS and cardiovascular diseases: a community-based study in the Matsu area
- Anti-thyroid-stimulating hormone receptor antibodies determined by second-generation assay
- Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients
- Surrogate markers of insulin resistance in assessing individuals with new categories “prehypertension” and “prediabetes”
- Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability
- Hyperhomocysteinaemia and immune activation in patients with cancer
- The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers
- Lipid peroxidation in Down syndrome caused by regular trisomy 21, trisomy 21 by Robertsonian translocation and mosaic trisomy 21
- Pregnancy-associated plasma protein A in dialysis patients
- L-Cysteine supplementation prevents exercise-induced alterations in human erythrocyte membrane acetylcholinesterase and Na+,K+-ATPase activities
- Assessment of homocysteine, neopterin and nitric oxide levels in Behcet's disease
- Increased adenosine deaminase in hydatidiform mole
- Classification tree analysis for the discrimination of pleural exudates and transudates
- External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems
- Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine
- Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update
- Analytical validation of the new version of the Liaison N-Tact PTH assay
- Validation of an automated sensitive immunoassay for quantitation of cytokines in the sputum of cystic fibrosis patients
- Strong interference of hemoglobin concentration on CSF total protein measurement using the trichloroacetic acid precipitation method
- Correction of patient results for Beckman Coulter LX-20 assays affected by interference due to hemoglobin, bilirubin or lipids: a practical approach
- Acquiring a measurement system within the framework of standard ISO 15189
- Six Sigma and laboratory consultation
- ESR or LSRB, that is the question!
- Reply to the Letter written by Hardeman
- Natriuretic peptides. The hormones of the heart
Articles in the same Issue
- CCLM: Bringing advances in laboratory medicine to the “New World”
- Diagnostic approach to inherited bleeding disorders
- Linking laboratory and medication data: new opportunities for pharmacoepidemiological research
- Association between polymorphisms of ACE, B2AR, ANP and ENOS and cardiovascular diseases: a community-based study in the Matsu area
- Anti-thyroid-stimulating hormone receptor antibodies determined by second-generation assay
- Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients
- Surrogate markers of insulin resistance in assessing individuals with new categories “prehypertension” and “prediabetes”
- Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability
- Hyperhomocysteinaemia and immune activation in patients with cancer
- The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers
- Lipid peroxidation in Down syndrome caused by regular trisomy 21, trisomy 21 by Robertsonian translocation and mosaic trisomy 21
- Pregnancy-associated plasma protein A in dialysis patients
- L-Cysteine supplementation prevents exercise-induced alterations in human erythrocyte membrane acetylcholinesterase and Na+,K+-ATPase activities
- Assessment of homocysteine, neopterin and nitric oxide levels in Behcet's disease
- Increased adenosine deaminase in hydatidiform mole
- Classification tree analysis for the discrimination of pleural exudates and transudates
- External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems
- Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine
- Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update
- Analytical validation of the new version of the Liaison N-Tact PTH assay
- Validation of an automated sensitive immunoassay for quantitation of cytokines in the sputum of cystic fibrosis patients
- Strong interference of hemoglobin concentration on CSF total protein measurement using the trichloroacetic acid precipitation method
- Correction of patient results for Beckman Coulter LX-20 assays affected by interference due to hemoglobin, bilirubin or lipids: a practical approach
- Acquiring a measurement system within the framework of standard ISO 15189
- Six Sigma and laboratory consultation
- ESR or LSRB, that is the question!
- Reply to the Letter written by Hardeman
- Natriuretic peptides. The hormones of the heart
